Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7261192 | 0.86 | ALDH1A1 (0.42) | CYP1A2GAACDK2SMN1; SMN2ALDH1A1 | |
| SCHEMBL1496200 | 0.83 | IDO1 (0.39) | GAACDK2SMN1; SMN2ALDH1A1GSK3B | |
| SCHEMBL1593232 | 0.80 | ALDH1A1 (0.42) | GAACDK2SMN1; SMN2ALDH1A1GSK3B | |
| SCHEMBL1461245 | 0.78 | CDK2 (0.65) | CYP1A2GAADYRK1ACDK2SMN1; SMN2 | |
| SCHEMBL1593872 | 0.77 | DYRK1A (0.41) | CYP1A2GAADYRK1AALDH1A1GLA | |
| SCHEMBL1593429 | 0.77 | ALDH1A1 (0.42) | GAASMN1; SMN2ALDH1A1MAPTNPC1 | |
| SCHEMBL14236122 | 0.75 | IDO1 (0.42) | ALDH1A1GLAMAPK1MAPTPOLB | |
| SCHEMBL1593117 | 0.75 | IDO1 (0.53) | CDK2ALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL12726035 | 0.75 | DYRK1A (0.45) | DYRK1ACDK2GSK3BMAPK1 | |
| SCHEMBL914646 | 0.74 | GAA (0.54) | CYP1A2GAADYRK1ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2470532-A1 | 1H-PYRAZOLO [ 3, 4-B]PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157452-A1 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011025968-A1 | 1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157452-A1 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | BRAF, RAF1, ARAF | CYP1A2 3024/4885GAA 2940/4885DYRK1A 552/4885 |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | CYP1A2 1083/4885GAA 3107/4885DYRK1A 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.